Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Grah, JJ; Katalinic, D; Juretic, A; Santek, F; Samarzija, M.
Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer.
Tumori. 2014; 100(1):60-68
Doi: 10.1700/1430.15817
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Grah Josip Joachim
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- This paper deals with the clinical significance of the immunohistochemical expression of MAGE-A1, MAGE-A3/4 and NY-ESO-1 antigens in patients with non-small cell lung cancer (NSCLC). The study included 80 patients with NSCLC (40 with adenocarcinoma, 40 with squamous cell carcinoma) who had undergone surgery. MAGE-A1 and MAGE-A3/4 antigen expression was determined by an immunohistochemical method using the monoclonal antibody 57B, and NY-ESO-1 antigen expression was determined with the addition of the B9.8.1.1 antibody. The expression of these antigens was compared with the clinicopathological features of the tumors and the survival of the patients. MAGE-A1, MAGE-A3/4 and NY-ESO-1 were expressed in 17.3%, 44.4% and 18.5% of NSCLC patients, respectively. A statistically higher immunohistological expression rate of MAGE-A3/4 was found in squamous cell carcinoma (P <0.001) and a significantly higher amount of tumor necrosis was observed in tumors with MAGE-3 expression (P = 0.001), but no correlation with positive lymph nodes was found. There was a statistically significant correlation between MAGE-A1 expression in adenocarcinoma and the presence of tumor necrosis (P = 0.05). Furthermore, there was a significant correlation between NY-ESO-1 expression and positive lymph nodes in adenocarcinoma, but not in squamous cell carcinoma. No statistically significant difference in patient survival was found with regard to tumor type and the observed histopathological characteristics except tumor size. Statistically significantly better survival was found in the group of patients with adenocarcinomas who had positive expression of MAGE-A3/4 (P = 0.012). This study demonstrated that the expression of MAGE-A3/4 antigen might be a valuable prognostic factor regarding survival in patients with NSCLC.
- Find related publications in this database (using NLM MeSH Indexing)
- Adenocarcinoma - chemistry
- Adult -
- Aged -
- Aged, 80 and over -
- Antigens, Neoplasm - analysis
- Biomarkers, Tumor - analysis
- Carcinoma, Non-Small-Cell Lung - chemistry
- Carcinoma, Non-Small-Cell Lung - mortality
- Carcinoma, Non-Small-Cell Lung - pathology
- Carcinoma, Squamous Cell - chemistry
- Female -
- Gene Expression Regulation, Neoplastic -
- Humans -
- Immunohistochemistry -
- Kaplan-Meier Estimate -
- Lung Neoplasms - chemistry
- Lung Neoplasms - mortality
- Lung Neoplasms - pathology
- Lymphatic Metastasis -
- Male -
- Melanoma-Specific Antigens - analysis
- Membrane Proteins - analysis
- Middle Aged -
- Neoplasm Grading -
- Neoplasm Proteins - analysis
- Neoplasm Staging -
- Testicular Neoplasms - chemistry
- Find related publications in this database (Keywords)
- non-small cell lung cancer
- MAGE-A1
- MAGE-A3/4
- NY-ESO-1